The new facility, based in Los Angeles, California is anticipated to be operational in 2013 and will expand the Company's ability to supply its new generation of intravenous immune globulin into the foreseeable future.
LOS ANGELES, Oct. 6 /PRNewswire/ -- Today, Grifols SA (Grifols), a global healthcare company based in Barcelona, Spain, broke ground on a new 92,000 square foot, intravenous immune globulin (IVIG) production facility at its manufacturing complex in Los Angeles, California. This new facility is the initial realization of the $600 million long-range investment plan announced in October 2007 to increase production for Grifols lifesaving coagulation therapies, immune globulins and albumin. Based on construction schedules and rigorous regulatory licensing requirements, it is expected that the facility will become operational for production of the Company's new generation IVIG product in early 2013.
The new facility represents an expansion of Grifols' existing manufacturing capabilities in Los Angeles. "We are committed to continuing to grow our state of the art facilities in Los Angeles and giving back to the community through the creation of new employment opportunities and economic growth," said Gregory Rich, President of Grifols, Inc. the US subsidiary of Grifols, SA. The new facility will provide approximately 300 new jobs to the Los Angeles community and represents an investment of greater than $50 million.
"We commend Grifols' increased commitment to the production of immune
globulin therapy. Assuring continued access to this lifesaving medicine
means countless people who live with primary immunodeficienies, such as my
son, can lead healthy and productive lives," said Marcia Boyle, President
and Founder of the Immune Deficiency Foundation, the national patient
organization for persons with primary immune diseases. Demand for IVIG has
seen steady growth over the past ten years in the US, Europe and other
|SOURCE Grifols SA|
Copyright©2008 PR Newswire.
All rights reserved